Neuphoria Therapeutics Price to Free Cash Flow Ratio 2022-2024 | NEUP

Neuphoria Therapeutics price to free cash flow ratio from 2022 to 2024. Price to free cash flow ratio can be defined as

Neuphoria Therapeutics Price to Free Cash Flow Ratio 2022-2024 | NEUP

Neuphoria Therapeutics price to free cash flow ratio from 2022 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$160.1B
Vertex Pharmaceuticals (VRTX)$123.9B
Gilead Sciences (GILD)$122.2B
Bristol Myers Squibb (BMY)$116.5B
CSL (CSLLY)$82.8B
Regeneron Pharmaceuticals (REGN)$79.3B
GSK (GSK)$75.4B
Argenex SE (ARGX)$40B
Alnylam Pharmaceuticals (ALNY)$35.9B
BioNTech SE (BNTX)$28.8B
BeiGene (ONC)$22.4B
Biogen (BIIB)$20.7B
Illumina (ILMN)$19.5B
Insmed (INSM)$14.5B
Incyte (INCY)$14.4B
Intra-Cellular Therapies (ITCI)$13.5B
Moderna (MRNA)$12.9B
Genmab (GMAB)$12.8B
Genmab (GNMSF)$12.7B
BioMarin Pharmaceutical (BMRN)$12.3B
Bio-Techne Corp (TECH)$11.9B
Vaxcyte (PCVX)$11.1B
Swedish Orphan Biovitrum (BIOVF)$10.9B
Sarepta Therapeutics (SRPT)$10.7B
Exact Sciences (EXAS)$10B
Bio-Rad Laboratories (BIO.B)$9.6B
Exelixis (EXEL)$9.6B
QIAGEN (QGEN)$9.4B
Repligen (RGEN)$9.1B
Roivant Sciences (ROIV)$7.9B